Charles Pauling Semba - Net Worth and Insider Trading
Charles Pauling Semba Net Worth
The estimated net worth of Charles Pauling Semba is at least $121,868 dollars as of 2024-09-20. Charles Pauling Semba is the Director of DiaMedica Therapeutics Inc and owns about 29,943 shares of DiaMedica Therapeutics Inc (DMAC) stock worth over $121,868. Details can be seen in Charles Pauling Semba's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Charles Pauling Semba has not made any transactions after 2023-06-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Charles Pauling Semba
Charles Pauling Semba Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Charles Pauling Semba owns 1 companies in total, including DiaMedica Therapeutics Inc (DMAC) .
Click here to see the complete history of Charles Pauling Semba’s form 4 insider trades.
Insider Ownership Summary of Charles Pauling Semba
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
DMAC | DiaMedica Therapeutics Inc | 2023-06-23 | director |
Charles Pauling Semba Latest Holdings Summary
Charles Pauling Semba currently owns a total of 1 stock. Charles Pauling Semba owns 29,943 shares of DiaMedica Therapeutics Inc (DMAC) as of June 23, 2023, with a value of $121,868.
Latest Holdings of Charles Pauling Semba
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
DMAC | DiaMedica Therapeutics Inc | 2023-06-23 | 29,943 | 4.07 | 121,868 |
Holding Weightings of Charles Pauling Semba
Charles Pauling Semba Form 4 Trading Tracker
According to the SEC Form 4 filings, Charles Pauling Semba has made a total of 1 transactions in DiaMedica Therapeutics Inc (DMAC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in DiaMedica Therapeutics Inc is the acquisition of 12,787 shares on June 23, 2023, which cost Charles Pauling Semba around $49,997.
Insider Trading History of Charles Pauling Semba
- 1
Charles Pauling Semba Trading Performance
GuruFocus tracks the stock performance after each of Charles Pauling Semba's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Charles Pauling Semba is -34.12%. GuruFocus also compares Charles Pauling Semba's trading performance to market benchmark return within the same time period. The performance of stocks bought by Charles Pauling Semba within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Charles Pauling Semba's insider trading performs compared to the benchmark.
Performance of Charles Pauling Semba
Charles Pauling Semba Ownership Network
Charles Pauling Semba Owned Company Details
What does DiaMedica Therapeutics Inc do?
Who are the key executives at DiaMedica Therapeutics Inc?
Charles Pauling Semba is the director of DiaMedica Therapeutics Inc. Other key executives at DiaMedica Therapeutics Inc include 10 percent owner Jan Stahlberg , 10 percent owner Koch Thomas Von , and CFO and Secretary Scott Kellen .
DiaMedica Therapeutics Inc (DMAC) Insider Trades Summary
Over the past 18 months, Charles Pauling Semba made 1 insider transaction in DiaMedica Therapeutics Inc (DMAC) with a net purchase of 12,787. Other recent insider transactions involving DiaMedica Therapeutics Inc (DMAC) include a net purchase of 527,114 shares made by David J. Wambeke , a net purchase of 2,670,588 shares made by Koch Thomas Von , and a net purchase of 1,200,000 shares made by Jan Stahlberg .
In summary, during the past 3 months, insiders sold 0 shares of DiaMedica Therapeutics Inc (DMAC) in total and bought 2,400,000 shares, with a net purchase of 2,400,000 shares. During the past 18 months, 0 shares of DiaMedica Therapeutics Inc (DMAC) were sold and 4,536,639 shares were bought by its insiders, resulting in a net purchase of 4,536,639 shares.
DiaMedica Therapeutics Inc (DMAC)'s detailed insider trading history can be found in Insider Trading Tracker table.
DiaMedica Therapeutics Inc Insider Transactions
Charles Pauling Semba Mailing Address
Above is the net worth, insider trading, and ownership report for Charles Pauling Semba. You might contact Charles Pauling Semba via mailing address: Two Carlson Parkway, Suite 260, Minneapolis Mn 55447.